STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMRX
  4. [Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amneal Pharmaceuticals director Ted C. Nark increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a price of $0 per share, bringing his direct holdings to 325,848 shares.

The exercised units were part of a 34,819-unit award granted on May 6, 2025 that vested on May 7, 2026. On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one share of Class A Common Stock, with vesting tied to the company’s director vesting schedule.

Positive

  • None.

Negative

  • None.
Insider Nark Ted C
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 34,819 $0.00 --
Exercise Class A Common Stock 34,819 $0.00 --
Grant/Award Restricted Stock Units 19,824 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Class A Common Stock — 325,848 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
RSUs Exercised 34,819 shares Restricted stock units converted to Class A Common Stock on May 7, 2026
Shares Held After 325,848 shares Direct Class A Common Stock holdings following the RSU exercise
New RSU Grant 19,824 units Restricted stock units granted on May 6, 2026 to director Ted C. Nark
RSU Conversion Price $0.00 per unit Stated transaction and conversion price for RSUs into Class A shares
Prior RSU Grant Size 34,819 units Restricted stock units granted on May 6, 2025, vesting May 7, 2026
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Class A Common Stock financial
"Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative security financial
"Transaction code M is described as an exercise or conversion of a derivative security."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nark Ted C
(Last)(First)(Middle)
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
(Street)
BRIDGEWATER NEW JERSEY 08807
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock05/07/2026M34,819A(1)325,848D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/07/2026M34,819 (2) (2)Class A Common Stock34,819$00D
Restricted Stock Units(1)05/06/2026A19,824 (3) (3)Class A Common Stock19,824$019,824D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
2. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.
3. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
Remarks:
/s/ Denis Butkovic, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Amneal (AMRX) director Ted C. Nark report in this Form 4?

Ted C. Nark reported stock-based compensation activity, not open-market trading. He exercised 34,819 restricted stock units into an equal number of Amneal Class A shares and received a new award of 19,824 restricted stock units tied to future vesting.

How many Amneal (AMRX) shares does Ted C. Nark hold after these transactions?

After exercising restricted stock units, Ted C. Nark directly holds 325,848 shares of Amneal Class A Common Stock. This reflects the addition of 34,819 shares received from the RSU conversion, as reported in the non-derivative holdings section of the Form 4.

Were any Amneal (AMRX) shares bought or sold on the open market in this Form 4?

No open-market purchases or sales were reported. The filing shows only stock-based compensation events: the exercise of 34,819 restricted stock units into Class A shares and the grant of 19,824 new restricted stock units, all at a stated price of $0 per unit.

What are the key details of the new restricted stock unit grant at Amneal (AMRX)?

On May 6, 2026, Ted C. Nark received 19,824 restricted stock units, each representing a contingent right to one Amneal Class A share. Vesting follows the company’s director vesting formula, based on the timing of annual stockholder meetings and the grant anniversary.

How did the previously granted Amneal (AMRX) RSUs vest for Ted C. Nark?

A prior award of 34,819 restricted stock units granted on May 6, 2025 vested on May 7, 2026. Upon vesting, these units were settled in 34,819 shares of Amneal Class A Common Stock, consistent with the company’s policy that each unit converts into one share.